Home › Research › Long-term cohort studies
Validation of a novel neuroimaging signature for dementia and clinical Alzheimer's disease in the population-based Rotterdam study
Jacqueline Josephine Claus, Mathijs T. Rosbergen, Gennady V. Roshchupkin, M. Arfan Ikram, Meike Willemijn Vernooij, Frank J. Wolters. Journal of Alzheimer s Disease, 2025-02-16
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
BackgroundA novel neuroimaging signature of regional cortical thickness on brain MRI recently showed high potential for Alzheimer's disease and related dementias (ADRD) risk stratification in the community. How these findings translate to other populations, remains undetermined.ObjectiveWe aimed to replicate this novel ADRD neuroimaging marker in the population-based Rotterdam Study.MethodsWe included all participants from the population-based Rotterdam Study with brain-MRI between 2005-2016, and derived the signature using FreeSurfer. We computed hazard ratios and C-statistics for 10-year dementia risk, and betas for cross-sectional associations with cognition, comparing the novel signature to hippocampal volume, mean cortical thickness, and another cortical thickness signature (Dickerson's).ResultsOf 3249 participants (mean age 71.3 ± 8.0 years), 294 developed dementia (74.8% clinical AD) during a mean follow-up of 8.1 years. The novel ADRD signature had similar magnitude of associations as Dickerson's signature and cortical thickness for AD dementia (HR per 1-SD increase 0.87;0.78-0.96), but performed worse than all markers for all-cause dementia. Of the four neuroimaging markers, hippocampal volume showed the strongest associations with both risk of all-cause dementia and clinical AD dementia. The ADRD had the weakest association with general cognitive function (β per 1-SD increase 0.04;0.02-0.06), and executive function (β per 1-SD increase 0.02;0.00-0.04), followed by cortical thickness and Dickerson's, and hippocampal volume showed the strongest associations.ConclusionsIn this community-based study, the novel cortical thickness signature did not outperform hippocampal volume for dementia risk stratification. The importance of replication studies underlines the value of the current study. Replicating research findings is essential to establish robust biomarkers for dementia risk prediction.
What this study adds
Evidence grade: Low
This is a cross-sectional study of 3,249 participants. This study tried to replicate a novel neuroimaging signature for dementia risk in the Rotterdam Study and found it performed worse than other markers for all-cause dementia, with hippocampal volume showing the strongest associations. Reported effect size: 74.8%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Claus, J. J., Rosbergen, M. T., Roshchupkin, G. V., Ikram, M. A., Vernooij, M. W., & Wolters, F. J. (2025). Validation of a novel neuroimaging signature for dementia and clinical Alzheimer's disease in the population-based Rotterdam study. Journal of Alzheimer s Disease. https://doi.org/10.1177/13872877251315044
Vancouver
Claus JJ, Rosbergen MT, Roshchupkin GV, Ikram MA, Vernooij MW, Wolters FJ. Validation of a novel neuroimaging signature for dementia and clinical Alzheimer's disease in the population-based Rotterdam study. Journal of Alzheimer s Disease. 2025. doi:10.1177/13872877251315044. PMID: 39956960.
BibTeX
@article{claus2025-39956960,
author = {Claus, Jacqueline Josephine and Rosbergen, Mathijs T. and Roshchupkin, Gennady V. and Ikram, M. Arfan and Vernooij, Meike Willemijn and Wolters, Frank J.},
title = {{Validation of a novel neuroimaging signature for dementia and clinical Alzheimer's disease in the population-based Rotterdam study}},
journal = {Journal of Alzheimer s Disease},
year = {2025},
doi = {10.1177/13872877251315044},
pmid = {39956960},
url = {https://doi.org/10.1177/13872877251315044}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- How these findings translate to other populations, remains undetermined.ObjectiveWe aimed to replicate this novel ADRD neuroimaging marker in the population-based Rotterdam Study.MethodsWe included all participants from the population-based Rotterdam Study with brain-MRI between 2005-2016, and derived the signature using FreeSurfer.
Why it matters
This study tried to replicate a novel neuroimaging signature for dementia risk in the Rotterdam Study and found it performed worse than other markers for all-cause dementia, with hippocampal volume showing the strongest associations. It suggests that this particular signature may not be as useful as hoped for risk stratification in the community.
Study details
- Study designcross-sectional
- Participants3,249
- Effect size74.8%
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 3,249 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Frank J. Wolters: h-index 46 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Erasmus MC: institution h-index 1,321 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39956960) |
| Free to read | 2 / 2 | Free to read |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1177/13872877251315044
- PubMed: 39956960
- Original source →
- Free full text: Journal of Alzheimer s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Long-term cohort studies from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.